Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) unit Teva UK Limited has announced the launch of generic Quetiapine film-coated tablets and Quetiapine (Sondate) XL tablets, on day one of patent expiry.
Quetiapine is a generic version of Seroquel (Quetiapine) by AstraZeneca UK Limited. It is indicated in the treatment of schizophrenia and the treatment of moderate to severe manic episodes. Quetiapine (Sondate) XL is a generic version of Seroquel XL by AstraZeneca UK Limited. It is indicated in the treatment of schizophrenia and bipolar disorder, and add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy.
Teva UK commercial director Kim Innes said: "With the launch of Quetiapine and Quetiapine XL, we're making more medicines accessible for more people. We've now launched ten new products in eleven weeks, including seven on day-one of patent-expiry. It adds to what is the UK's widest portfolio of medicines, with over 700 products. But, importantly launches like these help towards saving the NHS over £9bn on generic prescriptions."
2011 sales of Seroquel are estimated at $1.49 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on March 27, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012